24 completed, 7 terminated, 1 active not recruiting, 1 not yet recruiting. 33 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 33 | Completed 24, Terminated 7, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 6 | Completed 4, Terminated 2 |
Follow EMD Serono: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FSH and LH Versus FSH Alone for Ovarian Stimulation in Non-hormone Sensitive Onco-fertility Patients Luveris - Fertility Preservation | Phase 3 | Not yet recruiting | Ellen Greenblatt | 140 | 2024-02-01 | 2024-01-29 |
| Adjuvant Avelumab in Merkel Cell Cancer Avelumab, Peripheral Blood Collection, Placebo - Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8 | Phase 3 | Active not recruiting | University of Washington | 101 | 2017-12-19 | 2026-06-15 |
| Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) Avelumab, Utomilumab, Rituximab - Diffuse Large B-Cell Lymphoma | Phase 3 | Terminated | Pfizer | 29 | 2016-12-16 | 2020-12-17 |
| Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer Tecemotide, Placebo, Cyclophosphamide (CPA) - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | EMD Serono | 35 | 2014-03-01 | 2017-08-23 |
| Growth Hormone in Poor Responders to IVF Trial Saizen (Human Growth Hormone), No Saizen Control (Standard IVF Protocol) - Infertility | Phase 2 / Phase 3 | Terminated | Pacific Centre for Reproductive Medicine | 60 | 2012-06-01 | 2014-07-23 |
| Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study Saizen® - Growth Hormone Deficiency (GHD) | Phase 3 | Terminated | EMD Serono | 59 | 2010-10-01 | 2013-08-07 |
| A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study RebiSmart™ - Multiple Sclerosis | Phase 3 | Completed | EMD Serono | 103 | 2010-01-01 | 2013-08-08 |
| The Multicenter, Open-label, Single-use Autoinjector Convenience Study Rebidose® - Multiple Sclerosis | Phase 3 | Completed | EMD Serono | 109 | 2009-10-01 | 2013-08-07 |
| STRIDE - STimulating Immune Response In aDvanced brEast Cancer Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide - Breast Cancer | Phase 3 | Terminated | EMD Serono | 16 | 2009-09-01 | 2014-07-24 |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Cilengitide, Temozolomide, Radiotherapy - Glioblastoma | Phase 3 | Completed | EMD Serono | 545 | 2008-09-01 | 2014-11-04 |
| 12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis. Rebif® New Formulation (RNF) using RebiSmartTM - Multiple Sclerosis | Phase 3 | Completed | EMD Serono | 106 | 2008-07-01 | 2013-11-14 |
| Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) Atacicept 75 mg, Atacicept 150 mg, Placebo Comparator - Lupus Erythematosus, Systemic | Phase 2 / Phase 3 | Completed | EMD Serono | 461 | 2008-01-01 | 2016-03-14 |
| The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis Atacicept, Mycophenolate mofetil, Placebo - Lupus Nephritis | Phase 2 / Phase 3 | Terminated | EMD Serono | 6 | 2007-12-01 | 2016-03-23 |
| Rebif New Formulation (RNF) Quality of Life (QOL) Study Rebif New Formulation Non Titrated, Rebif New Formulation Titrated - Relapsing Multiple Sclerosis | Phase 3 | Completed | EMD Serono | 232 | 2007-04-01 | 2013-08-07 |
| Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo - Non-small Cell Lung Cancer | Phase 3 | Completed | EMD Serono | 1513 | 2007-01-01 | 2015-11-20 |
| RNF and Betaseron® Tolerability Study New Formulation of rebif - human interferon beta-1a, Interferon beta -1b - Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 3 | Completed | EMD Serono | 129 | 2006-12-01 | 2013-08-07 |
| A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Cladribine 5.25 mg/kg, Cladribine 3.5 mg/kg, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | EMD Serono | 1326 | 2005-04-01 | 2014-02-07 |
| Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome Serostim - Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome | Phase 3 | Completed | EMD Serono | 126 | 2005-02-01 | 2013-08-07 |
| Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis Interferon-beta-1a FBS-free/HSA-free - Multiple Sclerosis | Phase 3 | Completed | EMD Serono | 260 | 2005-01-01 | 2015-07-15 |
| Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency recombinant human growth hormone - Childhood-onset Growth Hormone Deficiency, Pituitary Dwarfism | Phase 3 | Completed | EMD Serono | 31 | 2005-01-01 | 2013-08-07 |
Showing 20 of 33. Sign in to see all of them.
Multiple Sclerosis (4) · Multiple Sclerosis, Relapsing-Remitting (4) · Dwarfism, Pituitary (3) · Infertility (3) · Carcinoma, Non-Small-Cell Lung (2) · Dyskinesias (2) · HIV Infections (2) · Parkinson Disease (2) · Arthritis, Psoriatic (1) · Breast Neoplasms (1) · Carcinoma, Merkel Cell (1) · Dwarfism (1) · Glioblastoma (1) · HIV Wasting Syndrome (1) · Helping Behavior (1)
Human Growth Hormone (8) · Growth Hormone (6) · Cyclophosphamide (3) · L-BLP25 (3) · Interferon beta-1a (2) · Luteinizing Hormone, beta Subunit (2) · Sodium Chloride (2) · TACI receptor-IgG Fc fragment fusion protein (2) · avelumab (2) · sarizotan (2) · Adrenal Cortex Hormones (1) · Anastrozole (1) · Azacitidine (1) · Bendamustine Hydrochloride (1) · Cilengitide (1)
United States (22) · Canada (6) · Germany (6) · Australia (4) · Czechia (4) · Poland (4) · South Korea (4) · Spain (4) · Austria (3) · Belgium (3) · Israel (3) · Italy (3) · Russia (3) · Taiwan (3) · United Kingdom (3)
Fernando Dangond, MD (4) · Andriy Markivskyy, MD (1) · Bettina Stubinski, MD (1) · Eduardo Kelly, MD, MBA (1) · Elisabetta Verdun di Cantogno, MD (1) · Elizabeth Svanbert, MD, PhD (1) · Ellen Brady, M.D. MPH (1) · Ellen Greenblatt, MD FRCSC (1) · Gordon Francis, M.D. (1) · Maria Lopez-Bresnahan, M.D. (1) · Nelly Mauras, MD (1) · Norma Muurahainen, M.D. PhD (1) · Oscar Kashala, MD, PhD, DSc (1)
PMID 15076238, PMID 16193898, PMID 17022858, PMID 17654600, PMID 17692727, PMID 18175337, PMID 18755819, PMID 20089960, PMID 20433746, PMID 20718590, PMID 22017519, PMID 22325903, PMID 23216674, PMID 24331154, PMID 24951103, PMID 24976972, PMID 25163906, PMID 25722382, PMID 28140753, PMID 28255849, PMID 28817997, PMID 29992396, PMID 32447743, PMID 33969750, PMID 34370275, PMID 34687398, PMID 34870327, PMID 35003076, PMID 35019731, PMID 35920065, PMID 36017780, PMID 36017797, PMID 36346112, PMID 36532058, PMID 37332136, PMID 40443562
2008 (1), 2016 (1)